Influence of amyloid and apolipoprotein E on cognitive performance in a late middle-aged cohort

December 15, 2015

Authors: Michelle M Mielke, Mary M Machulda, Clinton E Hagen, Teresa J Christianson, Rosebud O Roberts, David S Knopman, Prashanthi Vemuri, Val J Lowe, Walter K Kremers, Clifford R Jack Jr, Ronald C Petersen

Journal: Alzheimer's & Dementia

DOI: 10.1016/j.jalz.2015.09.010.

Year Published: 2015


Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals.


We included 464 cognitively normal, test-naïve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, mean age of 62.7 (range, 51-71 years), enrolled in the Mayo Clinic Study of Aging. Participants completed multiple cognitive assessments, including a standard neuropsychological battery and the CogState computerized battery, over 30 months of follow-up. Linear mixed models were used to examine the effects of amyloid and APOE genotype on baseline cognition and cognitive decline.


Elevated amyloid was not associated with tests of episodic memory but did predict declines on tests of executive function. APOE genotype was not associated with cognition. Among APOE ɛ4 noncarriers, higher amyloid was predictive of decline on tests of executive function and on one episodic memory test.


Elevated amyloidosis and APOE genotype do not appear to exert a dramatic influence on cognition in middle age.

Copyright © 2015 The Alzheimer’s Association. Published by Elsevier Inc. All rights reserved.

Back to Publications